Loading patent…
AssigneeThe Johns Hopkins University School of Medicine
InventorsRichard Ambinder, Yiping Yang, Ivan Borrello, Hyam Levitsky
Estimating the term…
A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficient to induce or stimulate an immune response to the viral-associated disease or cancer, or (iii) an immunomodulator and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficient to induce or stimulate an immune response to the viral associated disease or cancer.
A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a gene encoding an immunomodulator and (ii) a gene encoding an antigen of Epstein-Barr virus (EBV).
A composition comprising a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV.
A composition comprising an immunomodulator and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV.
A method of inducing or stimulating an immune response in a human to an EBV-associated cancer, which method comprises administering to the human a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, in an amount sufficient to induce or stimulate an immune response, and simultaneously or sequentially, in either order, by the same route or a different route, a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, in an amount sufficient to induce to stimulate an immune response, whereupon an immune response to the EBV-associated cancer is induced or stimulated.
A method of inducing or stimulating an immune response in a human to an EBV-associated cancer, which method comprises administering to the human an immunomodulator in an amount sufficient to induce to stimulate an immune response, and simultaneously or sequentially, in either order, by the same route or a different route, a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, in an amount sufficient to induce to stimulate an immune response, whereupon an immune response to the EBV-associated cancer is induced or stimulated.
Dependencies are inferred from the claim text.